Get the Stockscreener App
22.21
0.91%
0.20
Immunome Inc stock is traded at $22.21, with a volume of 614.87K.
It is up +0.91% in the last 24 hours and up +12.46% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$22.01
Open:
$22.13
24h Volume:
614.87K
Relative Volume:
0.47
Market Cap:
$2.52B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-9.3339
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
-0.49%
1M Performance:
+12.46%
6M Performance:
-14.15%
1Y Performance:
+97.60%
1-Day Range:
$21.61
$22.42
1-Week Range:
$21.61
$23.08
52-Week Range:
$8.665
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.21 | 2.52B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome Inc (IMNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMNM|Immunome Inc|Price:22.220|Chg%:+0.210 - TradingKey
TradingKey - TradingKey
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Australia
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
IMNM Reiterates by Wedbush -- Price Target Maintained at $31 - GuruFocus
Immunome doses first patient in IM-3050 trial - grafa.com
Immunome doses first patient in IM-3050 cancer therapy trial By Investing.com - Investing.com South Africa
Immunome (IMNM) Begins Phase 1 Trial for IM-3050 in Advanced Sol - GuruFocus
Immunome doses first patient in IM-3050 cancer therapy trial - Investing.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire
Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus - Sahm
Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data - webull.com
Immunome stock up 32% in a month: Here's what you should know - MSN
What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout | AI
Immunome granted FDA review for tumor candidate - msn.com
What This Immunome Sale Means a Day Before a Big FDA Milestone - The Motley Fool
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS) - The Globe and Mail
Immunome Stock Up 32% in a Month: Here's What You Should Know - The Globe and Mail
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Form 4 Immunome Inc For: 9 July - Investing.com India
Form 4 Immunome Inc For: 9 July By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock - Investing.com
Truist Financial Maintains Immunome(IMNM.US) With Buy Rating - Moomoo
Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares - Stock Titan
H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com - Investing.com India
H.C. Wainwright reiterates Immunome stock rating on FDA filing - Investing.com
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review - Benzinga
Immunome secures FDA review for cancer drug varegacestat - grafa.com
Immunome granted FDA review for tumor candidate (IMNM:NASDAQ) - Seeking Alpha
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat - Investing.com
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat By Investing.com - Investing.com South Africa
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors - Caledonian Record
Immunome Says FDA Accepted NDA for Desmoid Tumors Drug - Moomoo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 7, 2026 - BioSpace
Immunome director Isaac Barchas sells $2.4m in shares, price $24.11-$24.20 - Investing.com
Form 144 Immunome Inc. For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Immunome Inc For: 7 July By Investing.com - Investing.com Nigeria
Immunome director Isaac Barchas sells $2.4m in shares, price $24.11-$24.20 By Investing.com - Investing.com South Africa
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Horn Kinney | CHIEF BUSINESS OFFICER |
Jul 07 '26 |
Sale |
25.00 |
1,092 |
27,300 |
0 |
| Barchas Isaac | Director |
Jul 06 '26 |
Sale |
24.11 |
83,094 |
2,003,396 |
125,410 |
| Barchas Isaac | Director |
Jul 07 '26 |
Sale |
24.20 |
16,906 |
409,125 |
108,504 |
| Lechleider Robert | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
8.73 |
55,000 |
480,150 |
70,805 |
| Lechleider Robert | Chief Medical Officer |
Jul 02 '26 |
Sale |
22.62 |
55,000 |
1,244,331 |
15,805 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):